Defence Therapeutics

Defence Therapeutics appointed Dr. Mark Lambermon as Head of Quality and Operations to advance its Accum® technology. Dr. Lambermon brings over 20 years of pharmaceutical experience from companies like AbbVie and Baxter, specializing in GMP-compliant quality systems and CMC programs. His role will be crucial in scaling operations, ensuring regulatory readiness, and supporting strong pharma partnerships as Defence progresses with Accum®, which aims to enhance targeted delivery of Antibody-Drug Conjugates (ADCs). He received 100,000 immediately vested stock options.

Defence Therapeutics (DTCFF) appointed Dr. Amie Phinney to its Board of Directors. Dr. Phinney, previously a Strategy and Business Advisor, will now contribute to corporate governance and value creation as the company advances its drug-delivery platform. Defence granted her 100,000 stock options, exercisable at $0.75 per share. This appointment aims to enhance the company’s leadership and capitalize on Dr. Phinney’s pharma and biotech expertise, potentially impacting treatment landscapes.

Defence Therapeutics (DTCFF) announced a non-brokered private placement to raise up to $1.2 million by offering debenture units priced at $1,000 each. Each unit includes an 8% convertible debenture (convertible at $0.60 per share) maturing in two years and 1,666 common share purchase warrants (exercisable at $0.75 per share for two years). Interest will be paid annually in cash or shares at the company’s discretion. Securities are subject to a four-month hold. The offering aims to fund the company’s antibody-drug conjugate (ADC) programs.